An interventional study of 308-nm Excimer Light and Azithromycin in Acne Vulgaris, sponsored by Mahmoud Rageh. Completed at 1 site in Egypt. Open to participants aged 15 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Mahmoud Rageh · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Acne Vulgaris with a site in Egypt — 10 open to participants now, 11 under way, 2 of them phase 3. Acne Vulgaris · Egypt.
Among the 39 studies in Acne Vulgaris with a site in Egypt, this one is the 24th largest by enrollment of the 31 interventional ones that give a count, is one of 8 that started in 2025, is one of 18 with no phase, and was the 35th registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →10 of the 39 studies in Acne Vulgaris with a site in Egypt are open now. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 15–49 · Women only
Aswan University · Sites in Egypt
Ages 18–40 · Healthy volunteers
Assiut University · Sites in Egypt
Ages 12–35
Venus Research Center · Sites in Egypt
Tanta University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 15 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 4 · Phase 4 4
First in 2016; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 60 across the 31 interventional studies, 84 across the 8 observational. Of the 22 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 39 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Mahmoud Rageh as lead sponsor.
Mahmoud Rageh has 1 study filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
3 of the studies in Acne Vulgaris with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07919886Phase 3Cairo UniversityEvaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of Inflammatory Facial Acne Vulgaris. | 2027-05-20 |
| NCT07822360Sohag UniversityPrevalence of Polyendocrine Metabolic Ovarian Syndrome in Patients Diagnosed With Acne Vulgaris in Sohag University Hospital | 2027-02-08 |
| NCT07296523Venus Research CenterExpert Consensus on the Use of Isotretinoin in Acne Vulgaris: A Delphi Study | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Acne Vulgaris with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, evaluator-blinded, split-face study evaluated whether adjunctive lesion-directed 308-nm excimer light improves inflammatory acne outcomes during oral azithromycin therapy. All participants received oral azithromycin 500 mg three times weekly for 8 weeks. One randomly allocated hemiface additionally received 308-nm excimer light twice weekly for 8 weeks, while the contralateral hemiface served as the azithromycin-only control. Papule and pustule counts and hemiface Investigator's Global Assessment were assessed through Week 8. Investigator's Global Assessment was reassessed at Week 16 after an 8-week treatment-free follow-up. We hypothesized that the excimer-treated hemiface would demonstrate greater reduction in total inflammatory-lesion count by Week 8.
Participants with bilateral inflammatory acne received oral azithromycin 500 mg after meals three times weekly for 8 weeks. One hemiface was randomized by coin toss to receive adjunctive lesion-directed 308-nm excimer light twice weekly for 8 weeks; the contralateral hemiface received no irradiation. The primary outcome was the within-participant between-side difference in change from baseline to Week 8 in total inflammatory lesion count, defined as papules plus pustules. Hemiface IGA was assessed through Week 16, following an 8-week treatment-free period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One randomly allocated hemiface received lesion-directed 308-nm excimer light twice weekly for 8 weeks in addition to the oral azithromycin received by all participants.
Device: 308-nm Excimer Light · Drug: Azithromycin
The contralateral hemiface received no excimer-light irradiation. All participants received oral azithromycin for 8 weeks.
Drug: Azithromycin
Monochromatic 308-nm excimer light was delivered using the KN-5000C device. Irradiation was lesion-directed and administered twice weekly for 8 weeks, with at least 48 hours between sessions, for a planned total of 16 sessions. Treatment began at 0.15 J/cm² and was increased according to erythema response and device dose settings, up to a maximum of 0.65 J/cm².
Description: Oral azithromycin 500 mg was administered after meals three times weekly for 8 weeks, corresponding to 24 scheduled doses.
Change From Baseline in Total Inflammatory-Lesion Count at Week 8
Papules and pustules were counted separately for each hemiface by a blinded evaluator. Total inflammatory-lesion count was calculated as the sum of papules and pustules. Change was calculated as the baseline count minus the Week-8 count; positive values indicated improvement. The primary comparison was the within-participant difference in change between the excimer-treated and control hemifaces.
Time frame: Baseline and Week 8
Change From Baseline in Papule Count at Week 8
Papules were counted separately for each hemiface by a blinded evaluator. Change was calculated as the baseline count minus the Week-8 count; positive values indicated improvement.
Time frame: Baseline and Week 8
Change From Baseline in Pustule Count at Week 8
Pustules were counted separately for each hemiface by a blinded evaluator. Change was calculated as the baseline count minus the Week-8 count; positive values indicated improvement.
Time frame: Baseline and Week 8
Percentage Reduction in Total Inflammatory-Lesion Count at Week 8
Percentage reduction was calculated separately for each hemiface as 100 × (baseline total inflammatory-lesion count minus Week-8 total inflammatory-lesion count) divided by the baseline count. Higher percentages indicated greater improvement.
Time frame: Baseline and Week 8
Proportion of Hemifaces With at Least 50% Reduction in Total Inflammatory-Lesion Count
A responder was defined as a hemiface achieving at least a 50% reduction in total inflammatory-lesion count from baseline to Week 8.
Time frame: Baseline and Week 8
Proportion of Hemifaces With at Least 80% Reduction in Total Inflammatory-Lesion Count
A responder was defined as a hemiface achieving at least an 80% reduction in total inflammatory-lesion count from baseline to Week 8.
Time frame: Baseline and Week 8
Hemiface Investigator's Global Assessment Grade Over Time
Acne severity was graded separately for each hemiface by a blinded evaluator using a five-category Investigator's Global Assessment scale ranging from 0 to 4, where 0 indicated clear skin and 4 indicated severe acne. Lower grades indicated lower acne severity.
Time frame: Baseline, Week 4, Week 8, and Week 16
Participant Satisfaction With Each Hemiface
At Week 8, participants rated their satisfaction with each hemiface separately using an unvalidated numerical rating scale from 0 to 100. Higher scores indicated greater satisfaction.
Time frame: Week 8
Incidence of Solicited Local and Systemic Adverse Events
Solicited local events included procedural pain, erythema, irritation, burning, dryness, blistering, and pigmentary alteration. Solicited systemic symptoms potentially associated with azithromycin included gastrointestinal symptoms, hypersensitivity reactions, palpitations, dizziness or syncope, and symptoms suggestive of hepatic dysfunction. Severity was classified as absent, mild, moderate, or severe.
Time frame: From the first treatment through Week 16
Plan to share: No — Deidentified individual participant data will not be shared because the original participant consent and institutional ethics framework did not prospectively authorize external sharing of participant-level data.
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Mar 2026, 4 months.
Of 58 non-industry interventional studies with no phase under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's 4 months is below that.
Counting every sponsor, half of 120 studies reached it within 9 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.